Brokers Issue Forecasts for Altimmune FY2029 Earnings

Altimmune, Inc. (NASDAQ:ALT) – Equities researchers at HC Wainwright issued their FY2029 earnings estimates for shares of Altimmune in a research report issued on Wednesday, January 22nd. HC Wainwright analyst P. Trucchio forecasts that the company will post earnings of $1.30 per share for the year. HC Wainwright currently has a “Buy” rating and a $12.00 price target on the stock. The consensus estimate for Altimmune’s current full-year earnings is ($1.35) per share.

ALT has been the topic of several other reports. Stifel Nicolaus assumed coverage on shares of Altimmune in a research note on Wednesday, January 8th. They set a “buy” rating and a $18.00 price objective on the stock. UBS Group began coverage on shares of Altimmune in a research report on Tuesday, November 12th. They set a “buy” rating and a $26.00 target price on the stock. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $20.83.

Altimmune Stock Down 1.1 %

NASDAQ ALT opened at $6.98 on Monday. The stock has a market cap of $496.42 million, a P/E ratio of -4.50 and a beta of 0.22. The company’s 50-day simple moving average is $7.88 and its 200 day simple moving average is $7.20. Altimmune has a twelve month low of $5.28 and a twelve month high of $14.84.

Altimmune (NASDAQ:ALT) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.03. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. The company had revenue of $0.01 million for the quarter. During the same quarter in the previous year, the firm posted ($0.39) EPS.

Institutional Trading of Altimmune

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Larson Financial Group LLC bought a new position in Altimmune in the 3rd quarter valued at about $31,000. 180 Wealth Advisors LLC bought a new stake in shares of Altimmune during the 4th quarter valued at approximately $78,000. XTX Topco Ltd bought a new stake in Altimmune during the 2nd quarter worth approximately $96,000. PFG Investments LLC bought a new stake in Altimmune during the 4th quarter worth approximately $96,000. Finally, Stifel Financial Corp grew its holdings in Altimmune by 77.4% during the 3rd quarter. Stifel Financial Corp now owns 17,752 shares of the company’s stock worth $109,000 after acquiring an additional 7,746 shares during the last quarter. Institutional investors and hedge funds own 78.05% of the company’s stock.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.